<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831257</url>
  </required_header>
  <id_info>
    <org_study_id>15-590</org_study_id>
    <nct_id>NCT02831257</nct_id>
  </id_info>
  <brief_title>AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas</brief_title>
  <official_title>A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the study drug AZD2014 can shrink&#xD;
      growing or symptomatic meningiomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety&#xD;
      and effectiveness of an investigational intervention to learn whether the intervention works&#xD;
      in treating a specific disease. &quot;Investigational&quot; means that the intervention is being&#xD;
      studied.&#xD;
&#xD;
      The goal of this clinical research study is to learn if the study drug AZD2014 can shrink&#xD;
      growing or symptomatic meningiomas. Based on laboratory research, the cellular pathways which&#xD;
      are blocked by AZD2014 are important for the growth and survival of meningiomas. Further&#xD;
      treatment of meningioma cells in the laboratory setting has resulted in decreased survival of&#xD;
      tumor cells. As such, the purpose of this research is to see whether treating your meningioma&#xD;
      with AZD2014 will result in tumor shrinkage. The safety of AZD2014 will also be studied. Your&#xD;
      physical state, your symptoms, changes in the size of the tumor, and laboratory findings&#xD;
      obtained while on-study will help the research team decide if AZD2014 is safe and effective&#xD;
      in patients with your condition.&#xD;
&#xD;
      AZD2014 is being studied in patients with various cancers as a single agent (a drug that is&#xD;
      used alone to treat the cancer) or in combination with a number of anticancer therapies.&#xD;
      Previous studies have also allowed investigators to determine the best dose and frequency of&#xD;
      AZD2014 to achieve anti-tumor effects while reducing the likelihood of side effects.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has not approved AZD2014 as a treatment for&#xD;
      any disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2016</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Response Rate for Target Meningioma</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number of Target Meningiomas with a Decrease in Tumor Volume of at least 20% Compared with Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>From date of registration until the date of first documented progression assessed up to 24 months</time_frame>
    <description>Kaplan-Meier methodology will be used to estimate progression-free survival, with the 95% confidence intervals based on Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival at 6 Month</measure>
    <time_frame>6 months of treatment</time_frame>
    <description>Number of target meningiomas without progression at 6 months. Progression is defined using Response Evaluation In Neurofibromatosis and Schwannomatosis (REiNS) criteria, as a 20% increase in the volume of target meningioma compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response Rate for Non-target Meningiomas</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The response rate is the number of non-target meningiomas with at least 20% decrease in volume compared to the baseline volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 Adverse Events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Grade 3 adverse events as assessed by CTCAE version 5 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response Rate of Vestibular Schwannomas</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Radiographic response rate is defined as the proportion of vestibular schwannomas with at least 20% decrease in tumor volume compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Specific Quality of Life</measure>
    <time_frame>Baseline, after 3 months of treatment, and off study (up to 24 months)</time_frame>
    <description>Neurofibromatosis 2 Impact on Quality of Life (NFTI-QOL) questionnaire. The total NFTI-QOL score ranges from 0 to 24. The total NFTI-QOL score is higher in people with higher morbidity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vestibular Schwannoma-Specific Quality of Life</measure>
    <time_frame>Baseline, after 3 months of treatment, and off study (up to 24 months)</time_frame>
    <description>Penn Acoustic Neuroma-Quality of Life (PAN-QOL) questionnaire. Scores are normalized to range from 0 to 100 with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 2 Adverse Events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Grade 2 adverse events as assessed by CTCAE version 5 guidelines</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Neurofibromatosis 2</condition>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>AZD2014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2014</intervention_name>
    <arm_group_label>AZD2014</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National&#xD;
             Institute of Health (NIH) criteria or Manchester criteria, or by detection of a&#xD;
             causative mutation in the NF2 gene.&#xD;
&#xD;
          -  Participants must have progressive or symptomatic meningioma. NOTE 1: Histologic&#xD;
             confirmation of meningioma is not required in the setting of compatible radiographic&#xD;
             appearance, NOTE2: progression is defined as an increase in target meningioma volume ≥&#xD;
             20% OR ≥ 3 mm during the past 2 years.&#xD;
&#xD;
             -- Subjects must have a target meningioma that is not amenable to surgery due to&#xD;
             patient preference or high risk for surgical complications&#xD;
&#xD;
          -  Participants must be willing and able to undergo regular MRI scans of the brain&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one meningioma ≥ 1.0 ml&#xD;
             that can be accurately measured by contrast-enhanced cranial MRI scan, performed&#xD;
             within 28 days of study registration.&#xD;
&#xD;
          -  Prior surgical resection and radiation therapy for the progressive meningioma are not&#xD;
             required for study enrollment.&#xD;
&#xD;
          -  Patients must have received less than 3 prior chemotherapy regimens for progressive&#xD;
             meningioma.&#xD;
&#xD;
          -  Patients receiving dexamethasone must be able to be treated with alternative&#xD;
             corticosteroids such as prednisone, prednisolone, or methylprednisolone in the opinion&#xD;
             of the treating physician.&#xD;
&#xD;
          -  Patients must have available an archival paraffin tumor block sufficient to generate&#xD;
             at least 20 unstained slides; or, if a paraffin tumor block is unavailable, at least&#xD;
             20 unstained slides.&#xD;
&#xD;
          -  Age ≥ 18 years at the time of study enrollment.&#xD;
&#xD;
          -  ECOG performance status ≤2 (Karnofsky ≥60%) with no deterioration over the previous 2&#xD;
             weeks&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Within 14 days of study registration, participants must have normal organ and marrow&#xD;
             function as defined below:&#xD;
&#xD;
               -  leukocytes ≥3,000/mcL&#xD;
&#xD;
               -  absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
               -  hemoglobin ≥90 g/L&#xD;
&#xD;
               -  platelets ≥100,000/mcL&#xD;
&#xD;
               -  total bilirubin ≤1.5 x institutional upper limit of normal&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x institutional upper limit of normal concurrent with&#xD;
                  creatinine clearance ≥50 mL/min (measured or calculated by Cockcroft and Gault&#xD;
                  equation), confirmation of creatinine clearance is only required when creatinine&#xD;
                  is &gt;1.5xULN&#xD;
&#xD;
               -  Urine protein ≤1+ on urine dipstick (if 2+ seen on first test, re-test at least&#xD;
                  24 hours later)&#xD;
&#xD;
               -  PT/INR/PTT (aPTT) &lt;1.5x institutional upper limit of normal&#xD;
&#xD;
          -  The effects of AZD2014 on the developing human fetus are unknown. For this reason and&#xD;
             because mTOR kinase inhibiting agents are known to be teratogenic, female patients&#xD;
             must be willing to use 2 forms of highly effective contraception (per institution&#xD;
             standards) from the time of screening until 4 weeks after discontinuing study, must&#xD;
             not be breast feeding and must have a negative pregnancy test prior to start of dosing&#xD;
             if of child bearing potential or must have evidence of non-childbearing potential by&#xD;
             fulfilling one of the following criteria at screening: (1) post-menopausal women,&#xD;
             defined as either women aged more than 50 years and amenorrhoeic for at least 12&#xD;
             months following cessation of all exogenous hormonal treatments, or, (2) women under&#xD;
             50 years old who have been amenorrhoeic for at least 12 months following the cessation&#xD;
             of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH)&#xD;
             and luteinizing hormone (LH) levels in the postmenopausal range for the institution.&#xD;
             Alternatively, women must have documentation of irreversible surgical sterilisation by&#xD;
             hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal&#xD;
             ligation.&#xD;
&#xD;
          -  Male patients should either be surgically sterile or willing to use an effective&#xD;
             barrier method of contraception during the study and for 16 weeks following the last&#xD;
             dose of study treatment if sexually active with a female of childbearing potential. If&#xD;
             not done previously, storage of sperm prior to receiving AZD2014 will be advised to&#xD;
             male patients with a desire to have children.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             prior to any study specific procedures, sampling, and analyses.&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide,&#xD;
             immunotherapy, other anticancer agents within 21 days of starting study treatment (not&#xD;
             including palliative radiotherapy at focal sites). Prior use of an investigational&#xD;
             monoclonal antibody therapy within 3 months, or prior use of nitrosoureas or mitomycin&#xD;
             C within 6 weeks. Patients must have recovered from acute toxicity due to&#xD;
             radiotherapy.&#xD;
&#xD;
          -  With the exception of alopecia, any unresolved toxicities from prior anti-tumor&#xD;
             treatments (excluding corticosteroids) should be no greater than CTCAE (Version 4.0)&#xD;
             Grade 1 at the time of study entry.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to entry to the study (excluding placement of&#xD;
             vascular access), or minor surgery (excluding tumor biopsies) within 14 days of first&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 21 days.&#xD;
&#xD;
          -  History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with&#xD;
             a similar chemical structure or class to AZD2014.&#xD;
&#xD;
          -  Exposure to potent or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP&#xD;
             if taken within the stated washout periods before the first dose of study treatment&#xD;
             (see Appendix B)&#xD;
&#xD;
          -  Exposure to sensitive or narrow therapeutic range substrates of the drug metabolizing&#xD;
             enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP,&#xD;
             OATP1B1, OATP1B3, OCT1 and OCT2 within the appropriate wash-out period (a minimum of 5&#xD;
             x reported elimination half-life) before the first dose of study treatment (see&#xD;
             Appendix B)&#xD;
&#xD;
          -  Any haemopoietic growth factors (e.g., filgrastim [granulocyte colony-stimulating&#xD;
             factor; G-CSF], sargramostim [granulocyte-macrophage colony-stimulating factor;&#xD;
             GM-CSF]) within 14 days prior to receiving study treatment..&#xD;
&#xD;
          -  Pre-treatment with other mTOR inhibitors may be allowed and should be discussed for&#xD;
             each protocol and tumor type separately&#xD;
&#xD;
          -  Current refractory nausea and vomiting, malabsorption syndrome, disease significantly&#xD;
             affecting gastrointestinal function, resection of the stomach or small bowel,&#xD;
             symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete&#xD;
             bowel obstruction.&#xD;
&#xD;
          -  Previous meningioma progression during treatment with other mTORC1/2 inhibitors (but&#xD;
             not mTORC1 inhibitors such as everolimus or other rapalogues)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, severe hepatic impairment, interstitial lung disease (bilateral, diffuse,&#xD;
             parenchymal lung disease), uncontrolled chronic renal diseases (glomerulonephritis,&#xD;
             nephrotic syndrome, Fanconi Syndrome or renal tubular acidosis), current unstable or&#xD;
             uncompensated respiratory or cardiac conditions, uncontrolled hypertension, active&#xD;
             bleeding diatheses, active hepatitis B or C infection, known active human&#xD;
             immunodeficiency virus (HIV) infection, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements. Screening for chronic conditions is&#xD;
             not required.&#xD;
&#xD;
          -  History of other malignancies, except: Malignancy treated with curative intent and&#xD;
             with no known active disease present for ≥5 years before the first dose of study drug&#xD;
             and felt to be at low risk for recurrence by treating physician, (2) adequately&#xD;
             treated non-melanoma skin cancer or lentigo maligna without evidence of disease, (3)&#xD;
             adequately treated carcinoma in situ without evidence of disease, or (4) Gleason 6&#xD;
             prostate cancer under observation.&#xD;
&#xD;
          -  Patients who have experienced any of the following procedures or conditions currently&#xD;
             or in the preceding 12 months:&#xD;
&#xD;
               -  coronary artery bypass graft&#xD;
&#xD;
               -  angioplasty&#xD;
&#xD;
               -  vascular stent&#xD;
&#xD;
               -  myocardial infarction&#xD;
&#xD;
               -  angina pectoris&#xD;
&#xD;
               -  congestive heart failure New York Heart Association Grade ≥2 ( ventricular&#xD;
                  arrhythmias requiring continuous therapy)&#xD;
&#xD;
               -  supraventricular arrhythmias including atrial fibrillation, which are&#xD;
                  uncontrolled&#xD;
&#xD;
               -  haemorrhagic or thrombotic stroke, including transient ischaemic attacks or any&#xD;
                  other central nervous system bleeding&#xD;
&#xD;
               -  History of drug abuse or alcohol abuse, as judged by the Investigator&#xD;
&#xD;
          -  Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline&#xD;
             (left ventricular ejection fraction [LVEF] &lt;55%. Appropriate correction to be used if&#xD;
             a MUGA is performed.&#xD;
&#xD;
          -  Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi&#xD;
             Syndrome or renal tubular acidosis&#xD;
&#xD;
          -  Mean resting corrected QT interval (QTc), calculated using Fridericia's formula, &gt; 470&#xD;
             msec obtained from 3 electrocardiograms (ECGs), family or personal history of long or&#xD;
             short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de&#xD;
             Pointes within 12 months of the patient entering in the study&#xD;
&#xD;
          -  Patients with Diabetes Type I or uncontrolled Type II (HbA1c &gt;8% assessed locally) as&#xD;
             judged by the Investigator or Abnormal fasting glucose value defined as &gt;126 mg/dL (&gt;7&#xD;
             mmol/L).&#xD;
&#xD;
          -  Concomitant medications known to prolong QT interval, or with factors that increase&#xD;
             the risk of QTc prolongation or risk of arrhythmic events (such as heart failure,&#xD;
             hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or&#xD;
             unexplained sudden death under 40 years-of-age).&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Judgment by the Investigator that the patient is unsuitable to participate in the&#xD;
             study and the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements. Note: patients who are likely to require surgery or radiation for&#xD;
             NF2-related tumors during the first year of treatment in the investigator's opinion&#xD;
             should not be enrolled on this clinical trial.&#xD;
&#xD;
          -  Pregnant women are excluded from this study because AZD2014 is an mTORC1/2 inhibiting&#xD;
             agent with the potential for teratogenic or abortifacient effects. Because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with AZD2014, breastfeeding should be discontinued if the&#xD;
             mother is treated with AZD2014.&#xD;
&#xD;
          -  HIV-positive participants on combination antiretroviral therapy are ineligible because&#xD;
             of the potential for pharmacokinetic interactions with AZD2014. In addition, these&#xD;
             participants are at increased risk of lethal infections when treated with&#xD;
             marrow-suppressive therapy.&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca,&#xD;
             CRO staff, and/or staff at the CPU)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Plotkin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>November 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Scott R. Plotkin, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neurofibromatosis 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02831257/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZD2014</title>
          <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD2014</title>
          <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="18" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiographic Response Rate for Target Meningioma</title>
        <description>Number of Target Meningiomas with a Decrease in Tumor Volume of at least 20% Compared with Baseline</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Response Rate for Target Meningioma</title>
          <description>Number of Target Meningiomas with a Decrease in Tumor Volume of at least 20% Compared with Baseline</description>
          <units>target meningiomas</units>
          <param>Count of Units</param>
          <units_analyzed>target meningiomas</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>target meningiomas</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival (PFS)</title>
        <description>Kaplan-Meier methodology will be used to estimate progression-free survival, with the 95% confidence intervals based on Greenwood's formula.</description>
        <time_frame>From date of registration until the date of first documented progression assessed up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS)</title>
          <description>Kaplan-Meier methodology will be used to estimate progression-free survival, with the 95% confidence intervals based on Greenwood's formula.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="24" upper_limit="NA">The median PFS is &quot;not reached&quot; with a 95% confidence interval of (24 months, infinity)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival at 6 Month</title>
        <description>Number of target meningiomas without progression at 6 months. Progression is defined using Response Evaluation In Neurofibromatosis and Schwannomatosis (REiNS) criteria, as a 20% increase in the volume of target meningioma compared with baseline</description>
        <time_frame>6 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival at 6 Month</title>
          <description>Number of target meningiomas without progression at 6 months. Progression is defined using Response Evaluation In Neurofibromatosis and Schwannomatosis (REiNS) criteria, as a 20% increase in the volume of target meningioma compared with baseline</description>
          <units>target meningiomas</units>
          <param>Count of Units</param>
          <units_analyzed>target meningiomas</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>target meningiomas</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Response Rate for Non-target Meningiomas</title>
        <description>The response rate is the number of non-target meningiomas with at least 20% decrease in volume compared to the baseline volume.</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Response Rate for Non-target Meningiomas</title>
          <description>The response rate is the number of non-target meningiomas with at least 20% decrease in volume compared to the baseline volume.</description>
          <units>non-target meningiomas</units>
          <param>Count of Units</param>
          <units_analyzed>non-target meningiomas</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>non-target meningiomas</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 Adverse Events</title>
        <description>Grade 3 adverse events as assessed by CTCAE version 5 guidelines</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 Adverse Events</title>
          <description>Grade 3 adverse events as assessed by CTCAE version 5 guidelines</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, acneifrom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Response Rate of Vestibular Schwannomas</title>
        <description>Radiographic response rate is defined as the proportion of vestibular schwannomas with at least 20% decrease in tumor volume compared to baseline</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Response Rate of Vestibular Schwannomas</title>
          <description>Radiographic response rate is defined as the proportion of vestibular schwannomas with at least 20% decrease in tumor volume compared to baseline</description>
          <units>vestibular schwannomas</units>
          <param>Count of Units</param>
          <units_analyzed>vestibular schwannomas</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>vestibular schwannomas</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Specific Quality of Life</title>
        <description>Neurofibromatosis 2 Impact on Quality of Life (NFTI-QOL) questionnaire. The total NFTI-QOL score ranges from 0 to 24. The total NFTI-QOL score is higher in people with higher morbidity.</description>
        <time_frame>Baseline, after 3 months of treatment, and off study (up to 24 months)</time_frame>
        <population>Analysis population is the participants who completed NFTI-QOL questionnaire at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Specific Quality of Life</title>
          <description>Neurofibromatosis 2 Impact on Quality of Life (NFTI-QOL) questionnaire. The total NFTI-QOL score ranges from 0 to 24. The total NFTI-QOL score is higher in people with higher morbidity.</description>
          <population>Analysis population is the participants who completed NFTI-QOL questionnaire at baseline</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Off study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vestibular Schwannoma-Specific Quality of Life</title>
        <description>Penn Acoustic Neuroma-Quality of Life (PAN-QOL) questionnaire. Scores are normalized to range from 0 to 100 with higher scores indicating better quality of life.</description>
        <time_frame>Baseline, after 3 months of treatment, and off study (up to 24 months)</time_frame>
        <population>Analysis population includes all participants who completed Pan-QOL questionnaires at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Vestibular Schwannoma-Specific Quality of Life</title>
          <description>Penn Acoustic Neuroma-Quality of Life (PAN-QOL) questionnaire. Scores are normalized to range from 0 to 100 with higher scores indicating better quality of life.</description>
          <population>Analysis population includes all participants who completed Pan-QOL questionnaires at baseline</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" lower_limit="38.7" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" lower_limit="28.9" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Off study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" lower_limit="20.5" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 2 Adverse Events</title>
        <description>Grade 2 adverse events as assessed by CTCAE version 5 guidelines</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2014</title>
            <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 2 Adverse Events</title>
          <description>Grade 2 adverse events as assessed by CTCAE version 5 guidelines</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acute kidney injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dyspareunia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD2014</title>
          <description>18 patients will be enrolled in this study in a single stage.&#xD;
AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.&#xD;
One cycle will consist of 28 days (1 cycle = 28 days).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyphophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>white blood cells decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>High cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Difficulty chewing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>amenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>vaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash, acneiform</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Plotkin</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-5369</phone>
      <email>splotkin@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

